PTC Therapeutics
PTC Therapeutics is a global biopharmaceutical company dedicated to transforming lives by developing innovative therapies for people living with rare diseases. With 25 years of scientific expertise, the company focuses on research platforms such as splicing and inflammation & ferroptosis to create groundbreaking treatments. PTC is committed to patient-centric approaches, clinical research, and making a positive impact on communities and the environment.
Industries
Nr. of Employees
Very Large (1000+)
PTC Therapeutics
500 Warren Corporate Center Drive, Warren, NJ 07059
Patents
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
US-12281083-B2
View Details
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
US-12281083-B2
View DetailsProducts
Sephience™ (sepiapterin)
A treatment for phenylketonuria (PKU) granted marketing authorization in Europe for children and adults.
Translarna™ (ataluren)
An approved medicine for Duchenne muscular dystrophy caused by a nonsense mutation.
Emflaza® (deflazacort)
An approved treatment for Duchenne muscular dystrophy.
Sephience™ (sepiapterin)
A treatment for phenylketonuria (PKU) granted marketing authorization in Europe for children and adults.
Translarna™ (ataluren)
An approved medicine for Duchenne muscular dystrophy caused by a nonsense mutation.
Emflaza® (deflazacort)
An approved treatment for Duchenne muscular dystrophy.
Services
Supporting healthcare providers with scientific information and resources to improve patient care.
Providing support and educational materials for patients and families living with rare diseases.
Offering information and updates for investors interested in PTC's developments.
Conducting and supporting clinical research to develop new treatments for rare diseases.
Supporting healthcare providers with scientific information and resources to improve patient care.
Providing support and educational materials for patients and families living with rare diseases.
Offering information and updates for investors interested in PTC's developments.
Conducting and supporting clinical research to develop new treatments for rare diseases.
News & Updates
PTC announced that Sephience™ was granted marketing authorization by the European Commission for the treatment of PKU.
PTC has been recognized with Gallup’s 2025 Exceptional Workplace Award for fostering a strong workplace culture.
PTC was awarded the BioTech AI Solution of the Year from the BioTech Breakthrough Awards.
An article about PTC's efforts to promote diversity and inclusion in the workplace.
PTC highlights its environmental sustainability efforts through global tree planting.
A story about PTC's advocacy and innovation efforts in Germany over the past decade.
PTC announced that Sephience™ was granted marketing authorization by the European Commission for the treatment of PKU.
PTC has been recognized with Gallup’s 2025 Exceptional Workplace Award for fostering a strong workplace culture.
PTC was awarded the BioTech AI Solution of the Year from the BioTech Breakthrough Awards.
An article about PTC's efforts to promote diversity and inclusion in the workplace.
PTC highlights its environmental sustainability efforts through global tree planting.
A story about PTC's advocacy and innovation efforts in Germany over the past decade.